Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities

Abstract

ZAC encodes a zinc finger protein with antiproliferative activity, is maternally imprinted and is a candidate for the tumor suppressor gene on 6q24. ZAC expression is frequently lost in breast and ovary tumor-derived cell lines and down-regulated in breast primary tumors. In this report, we describe ZACΔ2, an alternatively spliced variant of ZAC lacking the sequence encoding the two N-terminal zinc fingers. Messenger RNAs encoding ZAC or ZACΔ2 were equally abundant and both proteins were nuclear. ZACΔ2 displayed an improved transactivation activity and an enhanced affinity for a ZAC binding site, suggesting that the two N-terminal zinc fingers negatively regulated ZAC binding to its target DNA sequences. Both proteins were equally efficient in preventing colony formation, indicating similar overall antiproliferative activities. However, these activities resulted from a differential regulation of apoptosis vs cell cycle progression since ZACΔ2 was more efficient at induction of cell cycle arrest than ZAC, whereas it was the reverse for apoptosis induction. Hence, these data further underline that ZAC gene is critically controlled, both at the transcriptional level through imprinting and at the functional level through alternative splicing.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Abdollahi A, Bao R and Hamilton TC. . 1999 Oncogene 18: 6477–6487.

  • Abdollahi A, Godwin AK, Miller PD, Getts LA, Schultz DC, Taguchi T, Testa JR and Hamilton TC. . 1997a Cancer Res. 57: 2029–2034.

  • Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, Testa JR and Hamilton TC. . 1997b Oncogene 14: 1973–1979.

  • Bickmore WA, Oghene K, Little MH, Seawright A, van Heyningen V and Hastie ND. . 1992 Science 257: 235–237.

  • Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, Bockaert J, Theillet C, Spengler D and Journot L. . 1999 Oncogene 18: 3979–3988.

  • Cabanillas AM and Darling DS. . 1996 DNA Cell. Biol. 15: 643–651.

  • Cavé H, Polak M, Drunat S, Denamur E and Czernichow P. . 2000 Diabetes 49: 108–113.

  • Chappell SA, Walsh T, Walker RA and Shaw JA. . 1997 Br. J. Cancer 75: 1324–1329.

  • Chen X, Agarwal A and Giedroc DP. . 1998 Biochemistry 37: 11152–11161.

  • Chen X, Chu M and Giedroc DP. . 1999 Biochemistry 38: 12915–12925.

  • Chomczynski P and Sacchi N. . 1987 Anal. Biochem. 162: 156–159.

  • Devilee P, van Vliet M, van Sloun P, Dijkshoorn NK, Hermans J, Pearson PL and Cornelisse CJ. . 1991 Oncogene 6: 1705–1711.

  • Ferguson AW and Milner RDG. . 1970 Arch. Dis. Child. 45: 80–81.

  • Fuji H, Zhou W and Gabrielson E. . 1996 Genes Chrom. Cancer 16: 35–39.

  • Gardner RJ, Mackay DJG, Mungall AJ, Polychronakos C, Siebert R, Shield JPH, Temple IK and Robinson DO. . 2000 Hum. Mol. Genet. 9: 589–596.

  • Gogos JA, Hsu T, Bolton J and Kafatos FC. . 1992 Science 257: 1951–1955.

  • Hanas JS, Hazuda DJ, Bogenhagen DF, Wu FY-H and Wu C-W. . 1983 J. Biol. Chem. 258: 14120–14125.

  • Hsu T, Gogos JA, Kirsh SA and Kafotos FC. . 1992 Science 257: 1946–1950.

  • Huang SM and Stallcup MR. . 2000 Mol. Cell. Biol. 20: 1855–1867.

  • Kamiya M, Judson H, Okazaki Y, Kusakabe M, Muramatsu M, Takada S, Takagi N, Arima T, Wake N, Kamimura K, Satomura K, Hermann R, Bonthron DT and Hayashizaki Y. . 2000 Hum. Mol. Genet. 9: 453–460.

  • Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G and Van de Ven WJ. . 1997 Nature Genet. 15: 170–174.

  • Klug A and Schwabe JWR. . 1995 FASEB J. 9: 597–604.

  • Knudson AG. . 1971 Proc. Natl. Acad. Sci. USA 68: 820–823.

  • Knudson AG. . 1993 Proc. Natl. Acad. Sci. USA 90: 10914–10921.

  • Lassus P and Hibner U. . 1998 Nucleic Acid Res. 26: 5233–5234.

  • Mackay JP and Crossley M. . 1998 Trends Biol. Sci. 23: 1–4.

  • Miller J, McLachlan AD and Klug A. . 1985 EMBO J. 4: 1609–1614.

  • Negrini M, Sabbioni S, Possati L, Rattan S, Corallini A, Barbanti-Brodano G and Croce CM. . 1994 Cancer Res. 54: 1331–1336.

  • Nishizaki T, DeVries S, Chew K, Goodson III WH, Ljung B-M, Thor A and Waldman FM. . 1997 Genes Chrom. Cancer 19: 267–272.

  • Noviello C, Courjal F and Theillet C. . 1996 Clin. Cancer Res. 2: 1601–1606.

  • Orphanos V, McGown G, Hey J, Boyle JM and Santobanez-Koref M. . 1995 Br. J. Cancer 71: 290–293.

  • Queimado L, Lopes C, Du F, Martins C, Bowcock AM, Soares J and Lovett M. . 1999 Lab. Invest. 79: 583–589.

  • Read D and Manley JL. . 1992 EMBO J. 11: 1035–1044.

  • Scharnhorst V, Kranenburg O, van der Eb AJ and Jochemsen AG. . 1997 Cell Growth Differ. 8: 133–143.

  • Sheng ZM, Marchetti A, Buttitta F, Champene M-H, Campani D, Bistocchi M, Lidereau R and Callahan R. . 1996 Br. J. Cancer 73: 144–147.

  • Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J and Journot L. . 1997 EMBO J. 16: 2814–2825.

  • Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM, Haensch W, Guski H, Winzer K-J, Barrett JC and Scherneck S. . 1996 Oncogene 13: 677–685.

  • Trainor CD, Ghirlando R and Simpson MA. . 2000 J. Biol. Chem. 275: 28157–28166.

  • Varrault A, Ciani E, Apiou F, Bilanges B, Hoffmann A, Pantaloni C, Bockaert J, Spengler D and Journot L. . 1998 Proc. Natl. Acad. Sci. USA 95: 8835–8840.

Download references

Acknowledgements

This work was supported by grants from the Centre Nationale de la Recherche Scientifique, La Ligue Nationale contre le Cancer, L'Association pour la Recherche contre le Cancer (ARC), the European Commission (QLG3-CT-1999-00602) to L Journot and from the Deutsche Forschungsgemeinschaft (Sp 386/3-1) to D Spengler. B Bilanges is a recipient of predoctoral fellowships from the Ministère de l'Education Nationale, de la Recherche et de la Technologie and from the ARC. A Mazumdar is a recipient of postdoctoral fellowships from the Fondation pour la Recherche Médicale and the ARC.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bilanges, B., Varrault, A., Mazumdar, A. et al. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities. Oncogene 20, 1246–1253 (2001). https://doi.org/10.1038/sj.onc.1204237

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204237

Keywords

This article is cited by

Search

Quick links